In a recent study, flow cytometry showed that the liver metastatic CRC patients with high expression of CD133+ CD54+, CD133− CD54+, and CD133+ CD44+ CD54+ cellular subpopulations of circulating tumor cells had a worse survival than those patients with low expression. This evidence concerns the gene PROM1 and neoplasm.